Irish pharmaceutical company Elan has reported a net loss of $13.8 million for the third quarter.
That was down to continuing operations associated with the planned company buyout, according to a statement from the company.
Elan shareholders will get an opportunity to vote on Perrigo's proposed acquisition of the company in Dublin next month.
Earnings Before interest Taxes and Depreciations of $12.1 million was recorded for the third quarter, reflecting the first full quarter of the new royalty arrangements on Tysabri.
The company ended the quarter with almost $1.9 billion in cash and cash equivalents, and no debt.